India Pharma Outlook Team | Thursday, 31 July 2025
In a momentous advancement for lung cancer care in Ghana, AstraZeneca and Revna Biosciences have renewed their commitment to improve access to diagnosis and treatment.
Building on a strategic initiative announced in April 2025, this undertaking demonstrates a remarkable step forward in precision medicine for underserved communities in sub-Saharan Africa.
The collaboration has introduced targeted therapy for EGFR-mutated lung cancer for the first time in Ghana, establishing new treatment pathways for patients who have limited or no prior opportunity for treatment. This advancement indicates the commitment by our partners to transform oncology care in the region.
Also Read: How Early Detection is Transforming Cancer Treatment in India
As a result of these contributions, key achievements have includes new EGFR biomarker testing being implemented into the workflow of the major cancer centers, facilitating personalized treatment and a stronger platform for cancer care decision making; the bolstering of local healthcare providers capabilities through a dedicated lung cancer symposium and clinical training programme to improve the early accurate detection of lung cancer; and the integration of a scalable level system across providers connecting molecular diagnostics with individualized therapies to reduce time delays to access and treatments to reflect a patient-oriented approach.
Further building-out access to, and significantly improving the diagnostic and treatment pathways with new approaches, the partners also have developed a data platform, producing real-time clinical intelligence to better optimize clinical decision making and research projects on treatment resistance and long-term survival outcomes.
By embedding precision medicine into Ghana’s healthcare system, AstraZeneca and Revna Biosciences are setting a new standard in cancer care. Their work is also advancing genomic and real-world evidence strategies to guide future innovation. This expansion underscores a shared vision: bridging the gap in lung cancer care and making cutting-edge treatments accessible to all.
